Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTA Centessa Pharmaceuticals	$12.68 +0.6%	$12.65	$8.46 ▼ $19.09	$1.68B	1.48	713,894 shs	1.38 million shs
IRON Disc Medicine	$50.09 +0.1%	$46.67	$30.82 ▼ $68.73	$1.73B	0.73	345,768 shs	319,600 shs
SIGA Siga Technologies	$6.42 +1.9%	$6.00	$4.95 ▼ $12.83	$450.08M	0.93	727,268 shs	317,037 shs
TARS Tarsus Pharmaceuticals	$41.07 +4.2%	$45.27	$20.08 ▼ $57.28	$1.66B	0.83	698,959 shs	783,226 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTA Centessa Pharmaceuticals	+0.63%	+1.52%	+3.43%	-22.16%	+48.91%
IRON Disc Medicine	+0.08%	-1.51%	+0.80%	-5.90%	+15.04%
SIGA Siga Technologies	+1.90%	+1.26%	+5.77%	+13.83%	+1.58%
TARS Tarsus Pharmaceuticals	+4.19%	+0.27%	-8.75%	-17.71%	+50.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTA Centessa Pharmaceuticals	3.5467 of 5 stars	4.5	2.0	2.0	3.3	0.6
IRON Disc Medicine	2.2337 of 5 stars	3.5	2.0	2.0	2.5	0.0
SIGA Siga Technologies	2.7261 of 5 stars	0.0	3.0	3.2	0.8	3.1
TARS Tarsus Pharmaceuticals	2.1468 of 5 stars	3.5	0.0	2.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTA Centessa Pharmaceuticals	3.00	Buy	$27.89	119.94% Upside
IRON Disc Medicine	3.09	Buy	$96.70	93.05% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	62.32% Upside

Current Analyst Ratings Breakdown

Latest SIGA, IRON, TARS, and CNTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/16/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
6/11/2025	IRON Disc Medicine	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$89.00
6/2/2025	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00
5/28/2025	CNTA Centessa Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
5/27/2025	TARS Tarsus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$72.00
5/12/2025	IRON Disc Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$112.00 ➝ $120.00
5/8/2025	CNTA Centessa Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$6.00
5/8/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
5/5/2025	TARS Tarsus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$46.00 ➝ $51.00
5/2/2025	TARS Tarsus Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $84.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTA Centessa Pharmaceuticals	$6.85M	247.21	N/A	N/A	$3.05 per share	4.16
IRON Disc Medicine	N/A	N/A	N/A	N/A	$14.85 per share	N/A
SIGA Siga Technologies	$138.72M	3.31	$0.85 per share	7.53	$3.02 per share	2.13
TARS Tarsus Pharmaceuticals	$182.95M	9.43	N/A	N/A	$5.87 per share	7.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.81	N/A	N/A	N/A	N/A	-40.22%	-29.95%	8/12/2025 (Estimated)
IRON Disc Medicine	-$109.36M	-$3.92	N/A	N/A	N/A	N/A	-22.61%	-21.07%	8/6/2025 (Estimated)
SIGA Siga Technologies	$59.21M	$0.67	9.58	5.14	N/A	40.30%	25.21%	22.05%	7/30/2025 (Estimated)
TARS Tarsus Pharmaceuticals	-$115.55M	-$2.73	N/A	N/A	N/A	-44.91%	-39.72%	-25.74%	8/6/2025 (Estimated)

Latest SIGA, IRON, TARS, and CNTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.20	+$0.15	-$0.20	N/A	N/A
5/8/2025	Q1 2025	SIGA Siga Technologies	N/A	-$0.01	N/A	-$0.01	N/A	$7.04 million
5/7/2025	Q1 2025	IRON Disc Medicine	-$0.99	-$1.02	-$0.03	-$1.02	N/A	N/A
5/1/2025	Q1 2025	TARS Tarsus Pharmaceuticals	-$0.69	-$0.64	+$0.05	-$0.64	$72.50 million	$78.34 million
3/24/2025	Q4 2024	CNTA Centessa Pharmaceuticals	-$0.38	-$0.34	+$0.04	-$0.84	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest SIGA, IRON, TARS, and CNTA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/8/2025	SIGA Siga Technologies	special	$0.60		4/29/2025	4/29/2025	5/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTA Centessa Pharmaceuticals	0.28	14.37	14.37
IRON Disc Medicine	0.04	37.65	37.65
SIGA Siga Technologies	N/A	8.40	6.28
TARS Tarsus Pharmaceuticals	0.21	5.57	5.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTA Centessa Pharmaceuticals	82.01%
IRON Disc Medicine	83.70%
SIGA Siga Technologies	55.40%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
CNTA Centessa Pharmaceuticals	7.09%
IRON Disc Medicine	4.24%
SIGA Siga Technologies	1.95%
TARS Tarsus Pharmaceuticals	8.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTA Centessa Pharmaceuticals	200	133.55 million	124.09 million	Optionable
IRON Disc Medicine	30	34.63 million	33.17 million	Not Optionable
SIGA Siga Technologies	40	71.44 million	70.05 million	Optionable
TARS Tarsus Pharmaceuticals	50	42.01 million	38.25 million	Optionable

SIGA, IRON, TARS, and CNTA Headlines

Recent News About These Companies

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by Brokerages

June 17 at 1:32 AM | marketbeat.com

Tarsus Pharmaceuticals CCO sells $765,800 in stock

June 13, 2025 | investing.com

Tarsus Pharmaceuticals CCO sells $765,800 in stock

June 13, 2025 | investing.com

Assenagon Asset Management S.A. Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

June 12, 2025 | marketbeat.com

E. Ohman J or Asset Management AB Boosts Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

June 7, 2025 | marketbeat.com

Squarepoint Ops LLC Sells 51,329 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

June 7, 2025 | marketbeat.com

Stocks Showing Improving Market Leadership: Tarsus Pharmaceuticals Earns 87 RS Rating

June 6, 2025 | msn.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - Time to Sell?

June 5, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

June 5, 2025 | marketbeat.com

Wellington Management Group LLP Sells 8,552 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

June 4, 2025 | marketbeat.com

Tarsus Pharmaceuticals assumed with an Outperform at Oppenheimer

June 2, 2025 | msn.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by Oppenheimer

June 2, 2025 | marketbeat.com

Nuveen Asset Management LLC Sells 15,186 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

May 31, 2025 | marketbeat.com

Q2 Earnings Forecast for TARS Issued By HC Wainwright

May 30, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Ameriprise Financial Inc.

May 30, 2025 | marketbeat.com

Tarsus to Participate in Upcoming Investor Conferences

May 29, 2025 | globenewswire.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Position Lessened by Two Sigma Advisers LP

May 29, 2025 | marketbeat.com

Two Sigma Investments LP Has $5.05 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

May 29, 2025 | marketbeat.com

Tarsus Pharmaceuticals' (TARS) Buy Rating Reaffirmed at HC Wainwright

May 28, 2025 | marketbeat.com

Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

May 27, 2025 | benzinga.com

TFG Asset Management GP Ltd Sells 414,117 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

May 27, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
3 Tech Stocks You Can't Miss in This Market Cycle
By Gabriel Osorio-Mazilli | June 17, 2025
View 3 Tech Stocks You Can't Miss in This Market Cycle

SIGA, IRON, TARS, and CNTA Company Descriptions

Centessa Pharmaceuticals NASDAQ:CNTA

$12.68 +0.08 (+0.63%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$13.29 +0.61 (+4.81%)

As of 06/18/2025 07:55 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Disc Medicine NASDAQ:IRON

$50.09 +0.04 (+0.08%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$50.10 +0.01 (+0.03%)

As of 06/18/2025 06:21 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Siga Technologies NASDAQ:SIGA

$6.42 +0.12 (+1.90%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$6.32 -0.10 (-1.50%)

As of 06/18/2025 07:56 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Tarsus Pharmaceuticals NASDAQ:TARS

$41.07 +1.65 (+4.19%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$41.05 -0.02 (-0.05%)

As of 06/18/2025 04:04 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time